[go: up one dir, main page]

UA117256C2 - Похідні амінопіримідину - Google Patents

Похідні амінопіримідину

Info

Publication number
UA117256C2
UA117256C2 UAA201603623A UAA201603623A UA117256C2 UA 117256 C2 UA117256 C2 UA 117256C2 UA A201603623 A UAA201603623 A UA A201603623A UA A201603623 A UAA201603623 A UA A201603623A UA 117256 C2 UA117256 C2 UA 117256C2
Authority
UA
Ukraine
Prior art keywords
pyrimidine derivatives
novel amino
amino pyrimidine
diseases
bruton
Prior art date
Application number
UAA201603623A
Other languages
English (en)
Inventor
Даніела Ангст
Франсуа Жесьє
Анна Вулпетті
Original Assignee
Новартіс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартіс Аг filed Critical Новартіс Аг
Publication of UA117256C2 publication Critical patent/UA117256C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Даний винахід описує нові похідні амінопіримідину формули (І) та їх фармацевтично прийнятні солі, які, як виявляється, взаємодіють з тирозинкіназою Брутона (Btk). Відповідно, нові амінопіримідини можуть бути ефективними при лікуванні аутоімунних розладів, запальних захворювань, алергійних захворювань, хвороб дихальних шляхів, таких як астма та обструктивна хвороба легенів (COPD), відторгнення трансплантата, ракових захворювань, наприклад гемопоетичного походження або солідних пухлин. (I)
UAA201603623A 2013-11-29 2014-11-28 Похідні амінопіримідину UA117256C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
PCT/IB2014/066422 WO2015079417A1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Publications (1)

Publication Number Publication Date
UA117256C2 true UA117256C2 (uk) 2018-07-10

Family

ID=49674216

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201603623A UA117256C2 (uk) 2013-11-29 2014-11-28 Похідні амінопіримідину

Country Status (42)

Country Link
US (6) US9512084B2 (uk)
EP (5) EP3299368B1 (uk)
JP (2) JP6342495B2 (uk)
KR (2) KR102380539B1 (uk)
CN (2) CN105683181B (uk)
AP (1) AP2016009158A0 (uk)
AR (1) AR098549A1 (uk)
AU (1) AU2014356069B2 (uk)
BR (1) BR112016010397B1 (uk)
CA (1) CA2926908C (uk)
CL (1) CL2016001055A1 (uk)
CR (1) CR20160244A (uk)
CU (1) CU24384B1 (uk)
CY (3) CY1119705T1 (uk)
DK (3) DK3689865T3 (uk)
EA (1) EA031218B1 (uk)
EC (1) ECSP16054826A (uk)
ES (4) ES2655527T3 (uk)
FI (1) FI3689865T3 (uk)
HR (3) HRP20171999T1 (uk)
HU (3) HUE062248T2 (uk)
IL (1) IL244943B (uk)
JO (1) JO3314B1 (uk)
LT (3) LT3689865T (uk)
MA (1) MA39055B1 (uk)
MX (1) MX367911B (uk)
MY (2) MY179059A (uk)
NO (1) NO3074386T3 (uk)
NZ (1) NZ718835A (uk)
PE (1) PE20160869A1 (uk)
PH (1) PH12016500791B1 (uk)
PL (3) PL3689865T3 (uk)
PT (3) PT3299368T (uk)
RS (3) RS64275B1 (uk)
SI (3) SI3299368T1 (uk)
SV (1) SV2016005206A (uk)
TN (1) TN2016000128A1 (uk)
TW (1) TWI652261B (uk)
UA (1) UA117256C2 (uk)
UY (1) UY35858A (uk)
WO (1) WO2015079417A1 (uk)
ZA (1) ZA201602275B (uk)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
MX395149B (es) 2014-04-07 2025-03-24 Novartis Ag Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
KR20210149228A (ko) 2014-09-17 2021-12-08 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
WO2016164580A1 (en) * 2015-04-07 2016-10-13 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CN119925616A (zh) 2015-04-08 2025-05-06 诺华股份有限公司 Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
WO2018017708A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
ES2961666T3 (es) 2016-12-03 2024-03-13 Juno Therapeutics Inc Métodos para determinar la dosificación de células CAR-T
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
AU2018291032A1 (en) 2017-06-29 2020-01-16 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
JP2021506260A (ja) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド 抗ｃｃｔ５結合分子およびその使用方法
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
JOP20210017A1 (ar) 2018-07-25 2021-01-21 Novartis Ag مثبطات جسيم التهابي nlrp3
IL281025B2 (en) 2018-08-29 2024-12-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
WO2020092848A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
EP3873937A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
EP3880238A1 (en) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
MX2021006238A (es) 2018-11-30 2021-10-01 Juno Therapeutics Inc Metodos para tratamiento que usan terapia celular adoptiva.
PE20212198A1 (es) 2019-01-29 2021-11-16 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
AU2020278236B2 (en) 2019-05-23 2025-08-07 Novartis Ag Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
CA3137790A1 (en) * 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor
ES3039974T3 (en) 2019-05-23 2025-10-28 Novartis Ag A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
EP4081514A1 (en) * 2019-12-23 2022-11-02 Biogen MA Inc. Btk inhibitors
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
PE20230855A1 (es) 2020-08-14 2023-05-29 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos
WO2022033569A1 (zh) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
US20250281413A1 (en) * 2021-01-26 2025-09-11 Novartis Ag Pharmaceutical composition
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
JP7564347B2 (ja) * 2021-09-03 2024-10-08 ノバルティス アーゲー 多発性硬化症を治療するためのｌｏｕ０６４
EP4448114A1 (en) 2021-12-14 2024-10-23 Novartis AG Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CA3263560A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
KR20250135354A (ko) 2022-12-13 2025-09-12 주노 쎄러퓨티크스 인코퍼레이티드 Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도
WO2025061148A1 (zh) * 2023-09-22 2025-03-27 江苏恒瑞医药股份有限公司 杂芳基类化合物、其制备方法及其在医药上的应用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
WO2025210469A2 (en) 2024-04-02 2025-10-09 Novartis Ag Process of preparing remibrutinib substantially free of nitrosamine impurity
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
JP2004533209A (ja) 2000-10-23 2004-11-04 ブリストル−マイヤーズ　スクイブ　カンパニー ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用
SG159378A1 (en) 2000-11-07 2010-03-30 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
EP2322200A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20050084224A (ko) 2002-12-09 2005-08-26 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 야누스 티로신 키나제 3을 선택적으로 저해하는 방법
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
BRPI0506817A (pt) 2004-01-12 2007-05-29 Cytopia Res Pty Ltd inibidores seletivos de quinase
US7947835B2 (en) 2005-03-10 2011-05-24 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2546651A1 (en) 2007-03-14 2013-01-16 Bionsil S.r.l. Modulator compounds of the drug resistance in epithelial tumour cells
ES2554615T3 (es) 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
RU2507202C2 (ru) 2008-07-02 2014-02-20 Ф.Хоффманн-Ля Рош Аг Новые фенилпиразиноны в качестве ингибиторов киназы
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2513915T3 (es) 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
WO2011104340A1 (en) * 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
US8703767B2 (en) 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
JP6068451B2 (ja) 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
JP2014517016A (ja) 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
AU2012275275A1 (en) 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
MX2014000338A (es) 2011-07-08 2014-05-01 Novartis Ag Derivados de pirrolo-pirimidina novedoso.
EP3778896A1 (en) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
EP2771010A4 (en) 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS
EP2770830A4 (en) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
BR112014013582A2 (pt) 2011-12-09 2017-06-13 Hoffmann La Roche inibidores de quinase de tirosina de bruton
US20150011751A1 (en) 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
US9133134B2 (en) 2012-05-16 2015-09-15 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2014025976A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
US9828376B2 (en) 2012-10-04 2017-11-28 University Of Utah Research Foundation Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
HRP20171999T1 (hr) 2018-02-09
HK1223368A1 (en) 2017-07-28
US20230312483A1 (en) 2023-10-05
US20180251432A1 (en) 2018-09-06
CA2926908A1 (en) 2015-06-04
US20150152068A1 (en) 2015-06-04
AU2014356069B2 (en) 2017-06-15
PT3299368T (pt) 2020-05-28
EP3689865B1 (en) 2023-03-29
AU2014356069A1 (en) 2016-05-05
PH12016500791A1 (en) 2016-06-13
DK3074386T3 (en) 2018-01-22
CU20160078A7 (es) 2016-09-30
BR112016010397A8 (pt) 2020-04-22
US9512084B2 (en) 2016-12-06
LT3689865T (lt) 2023-07-10
EP4606377A3 (en) 2025-11-26
PL3299368T3 (pl) 2020-08-10
CL2016001055A1 (es) 2016-10-28
TWI652261B (zh) 2019-03-01
ECSP16054826A (es) 2017-10-31
KR102421388B1 (ko) 2022-07-18
HRP20200775T1 (hr) 2020-07-24
NZ718835A (en) 2021-12-24
RS60251B1 (sr) 2020-06-30
SI3689865T1 (sl) 2023-07-31
TN2016000128A1 (en) 2017-10-06
MA39055A1 (fr) 2018-02-28
HRP20230585T1 (hr) 2023-09-01
WO2015079417A1 (en) 2015-06-04
CU24384B1 (es) 2019-03-04
DK3299368T3 (da) 2020-05-25
SI3074386T1 (en) 2018-02-28
US10457647B2 (en) 2019-10-29
SI3299368T1 (sl) 2020-07-31
ZA201602275B (en) 2017-08-30
ES2947770T3 (es) 2023-08-18
CN105683181B (zh) 2019-04-23
PE20160869A1 (es) 2016-09-08
KR20160088877A (ko) 2016-07-26
JP2016538313A (ja) 2016-12-08
JP6342495B2 (ja) 2018-06-13
CN110172056A (zh) 2019-08-27
AP2016009158A0 (en) 2016-04-30
EP3074386B1 (en) 2017-10-11
JP6667573B2 (ja) 2020-03-18
US20220041561A1 (en) 2022-02-10
CY1122924T1 (el) 2021-10-29
MX367911B (es) 2019-09-11
EP3074386A1 (en) 2016-10-05
PT3074386T (pt) 2017-11-15
EA031218B1 (ru) 2018-12-28
RS64275B1 (sr) 2023-07-31
US11180460B2 (en) 2021-11-23
IL244943A0 (en) 2016-05-31
UY35858A (es) 2015-06-30
ES3040769T3 (en) 2025-11-04
ES2791525T3 (es) 2020-11-04
EP4219478B1 (en) 2025-06-11
LT3074386T (lt) 2017-12-27
JP2018141005A (ja) 2018-09-13
NO3074386T3 (uk) 2018-03-10
AR098549A1 (es) 2016-06-01
PL3074386T3 (pl) 2018-03-30
MX2016006908A (es) 2016-08-17
HUE037588T2 (hu) 2018-09-28
US11673868B2 (en) 2023-06-13
PT3689865T (pt) 2023-06-16
SV2016005206A (es) 2016-11-21
KR102380539B1 (ko) 2022-03-29
PL3689865T3 (pl) 2023-07-31
IL244943B (en) 2020-04-30
EP4219478A1 (en) 2023-08-02
CY1119705T1 (el) 2018-06-27
PH12016500791B1 (en) 2016-06-13
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
HK1252317A1 (en) 2019-05-24
MY191381A (en) 2022-06-22
EP3299368A1 (en) 2018-03-28
CA2926908C (en) 2021-10-26
FI3689865T3 (fi) 2023-06-12
LT3299368T (lt) 2020-05-25
HUE049794T2 (hu) 2020-10-28
EP4606377A2 (en) 2025-08-27
RS56657B1 (sr) 2018-03-30
US20200010426A1 (en) 2020-01-09
CN105683181A (zh) 2016-06-15
CY1126056T1 (el) 2023-11-15
EP3299368B1 (en) 2020-02-26
DK3689865T3 (en) 2023-06-19
ES2655527T3 (es) 2018-02-20
TW201609666A (zh) 2016-03-16
MY179059A (en) 2020-10-26
MA39055B1 (fr) 2018-10-31
BR112016010397B1 (pt) 2023-04-11
CR20160244A (es) 2016-07-29
HUE062248T2 (hu) 2023-10-28
KR20220044370A (ko) 2022-04-07
EA201691125A1 (ru) 2016-09-30
US20160235746A1 (en) 2016-08-18
CN110172056B (zh) 2022-04-19

Similar Documents

Publication Publication Date Title
PH12016500791A1 (en) Novel amino pyrimidine derivatives
MX2014000338A (es) Derivados de pirrolo-pirimidina novedoso.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2013004298A (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
MX2016003457A (es) Compuestos aminopirimidina sustituidos y metodos de uso.
BR112015017338A2 (pt) anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
MX373151B (es) Composiciones y métodos para la producción de compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton (btk).
EA201590663A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
BR112017011798A2 (pt) 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase
EA202090258A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
TH180843A (th) อนุพันธ์อะมิโน ไพริมิดีนชนิดใหม่
MX370251B (es) Derivados de difeniloxialquilamina y derivados de ariloxialquilamina, composicion farmaceutica, uso de dicha composicion farmaceutica para tratar, prevenir o inhibir enfermedades inflamatorias pulmonares cronicas y metodo para tratar o prevenir dichas enfermedades.